title: [Diagnosis and treatment of epithelioid sarcoma].
abstract: OBJECTIVE
  To analyze the clinical features, diagnosis, treatment, and prognosis of epithelioid sarcoma (ES).
  
  
  METHODS
  The clinical data of 13 cases with epithelioid sarcoma in the Tianjin Medical University Cancer Institute and Hospital from March 1995 to December 2009 were collected and analyzed. There were 10 males and 3 females in the group, with an average age of 41.5 years (range: 13 to 68 years). Nine patients had classic ES and 4 had proximal-type ES. Surgery was the mainstay of treatment. After the operation, four patients received radiotherapy, five received chemotherapy, and one received chemoradiotherapy.
  
  
  RESULTS
  Of the 13 cases, only 1 had multi-locus lesion. The average tumor size was (6.07 ± 1.34) cm. The lymph node involvement was found in 46.2% of the patients. Local and distant failure occurred in 50% and 30% patients, respectively. The most common site for dissemination was the lung. Four cases died within 3 years after initial operation. The 1-, 2-, 5-, 10-year overall survival rates of the 11 cases were 72.7%, 54.5%, 27.3% and 9.1%, respectively, with a median survival time of 27 months.
  
  
  CONCLUSIONS
  Epithelioid sarcoma is a rare disease. The prognosis for patients with epithelioid sarcoma is poor because of a high propensity for local recurrence, lymph node metastases, and/or distant metastases. The definite diagnosis depends mainly on the pathologic examination. Wide surgical excision is the mainstay treatment, and radiation and chemotherapy have been used occasionally as adjuvant therapy but have had limited success.
authors.affiliation: Department of Integrative Medicine, Hospital of Tianjin Medical University, Tianjin, China.
authors.forename: Yan-min
authors.initials: YM
authors.lastname: Xing
authors.forename: Zhan-yu
authors.initials: ZY
authors.lastname: Pan
authors.forename: Yan-wei
authors.initials: YW
authors.lastname: Li
authors.forename: Hai-yan
authors.initials: HY
authors.lastname: Sun
authors.forename: Zhang-sheng
authors.initials: ZS
authors.lastname: Jang
authors.forename: Guang-ru
authors.initials: GR
authors.lastname: Xie
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D005121:Extremities; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000378:metabolism; D009364:Neoplasm Recurrence, Local; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012509:Sarcoma / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D012983:Soft Tissue Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D014746:Vimentin / Q000378:metabolism; D055815:Young Adult
chemical_list: D018396:Mucin-1; D014746:Vimentin